

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Sharp Laboratories of America Inc.	03/17/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SHARP KABUSHIKI KAISHA
<b>Street Address:</b>	22-22, Nagaïke-cho, Abeno-ku
<b>City:</b>	Osaka
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	545-8522
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7889790
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(360)817-7447
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	360-817-7583
<b>Email:</b>	ehudjohn@sharplabs.com
<b>Correspondent Name:</b>	Erin Hudjohn
<b>Address Line 1:</b>	5750 NW Pacific Rim Blvd.
<b>Address Line 4:</b>	Camas, WASHINGTON 98607
<b>ATTORNEY DOCKET NUMBER:</b>	SLA1775
<b>NAME OF SUBMITTER:</b>	David C. Ripma
<b>Total Attachments: 1</b> source=SLA1775 Corp-to-Corp Assign SLA to SC#page1.tif	

CH \$40.00 7889790

**Corporate to Corporate Assignment**

WHEREAS, SHARP LABORATORIES OF AMERICA, INC. (hereinafter "SLA"), a corporation of the State of Washington, having an address at 5750 NW Pacific Rim Blvd., Camas, Washington 98607, USA, is, by one or more assignment documents recorded in the United States Patent and Trademark Office, the present assignee and record owner of an interest in the following United States Letters Patent(s) (hereinafter "said patent(s)");

<u>Patent No.</u>	<u>Issue Date</u>	<u>SLA File No.</u>
7,889,790	February 15, 2011	SLA1775

and in the invention(s) to which said patent(s) pertain(s) (hereinafter "said invention"); and

WHEREAS, SHARP KABUSHIKI KAISHA (hereinafter "Sharp"), a Japanese Corporation, having an address at 22-22, Nagaïke-cho, Abeno-ku, Osaka, 545-8522, Japan, is the true and equitable owner of all patents which ultimately issue from patent applications filed by SLA covering inventions arising from research funded by Sharp under the terms of a mutual agreement between SLA and Sharp (hereinafter "said Basic Agreement"); and

WHEREAS, SLA and Sharp mutually acknowledge and agree that the terms of said Basic Agreement are applicable to said patent(s) and said invention(s) and that, by operation of said Basic Agreement, Sharp is, upon issuance of said patent(s), the true and equitable owner of any and all rights which SLA may possess in and to said patent(s) and said invention(s) and, furthermore, that Sharp is entitled to formal assignment of all of SLA's rights therein to Sharp, including recordation of such assignment in the records of the United States Patent and Trademark Office.

NOW, THEREFORE, for good and valuable consideration acknowledged by SLA to have been received in full from Sharp, SLA does hereby sell, assign, transfer, convey, and quitclaim unto Sharp all of SLA's right, title and interest in and to said patent(s) and said invention(s).

The terms and covenants of this Assignment shall inure to the benefit of Sharp, its successors, assigns and other legal representatives, and shall be binding upon SLA, its successors, assigns and other legal representatives.

The undersigned is authorized to act on behalf of the assignee in accordance with 37 CFR § 3.73(b)(2)(i).

**Sharp Laboratories of America, Inc.**

Dated: March 17, 2011

/David C. Ripma/  
\_\_\_\_\_  
David C. Ripma, Registration No. 27,672  
Patent Counsel